An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma

Overview

Journal Lung Cancer (Auckl)

Publisher Dove Medical Press

Date 2022 Mar 10

PMID 35264891

Authors

Alexander Davis

Helen Ke

Steven Kao

Nick Pavlakis

Affiliations

Soon will be listed here.

Abstract

The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; however, there is little randomised evidence to validate this approach. Prior to 2020 chemotherapy with platinum and an anti-folate was the only intervention with randomised evidence to demonstrate improved overall survival (OS) in MPM. No systemic therapy had been demonstrated to improve OS in the second line setting until 2020. The publication of the Checkmate 743 trial in 2021 demonstrated a survival benefit of combination immunotherapy over standard chemotherapy in newly diagnosed patients with MPM. This finding was shortly followed by the CONFIRM trial which demonstrates a modest but significant survival benefit of second line nivolumab versus placebo in patients having previously received standard chemotherapy. The results of these trials, recent biomarker directed therapy and chemotherapy adjuncts are discussed within this review. The integration of immunotherapy for the few patients in whom radical surgical therapy is intended is currently the subject of clinical trials and offers the prospect of improving outcomes in this rare but devastating disease.

Citing Articles

Comprehensive review of drug resistance in mammalian cancer stem cells: implications for cancer therapy.

Mengistu B, Tsegaw T, Demessie Y, Getnet K, Bitew A, Kinde M Cancer Cell Int. 2024; 24(1):406.

PMID: 39695669 PMC: 11657890. DOI: 10.1186/s12935-024-03558-0.

Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo.

Zhu R, Liu X, Zhang X, Zhong Z, Qi S, Jin R Cell Rep Med. 2024; 5(10):101763.

PMID: 39368484 PMC: 11513813. DOI: 10.1016/j.xcrm.2024.101763.

Diagnosis of Pleural Mesothelioma: Is Everything Solved at the Present Time?.

Roca E, Aujayeb A, Astoul P Curr Oncol. 2024; 31(9):4968-4983.

PMID: 39329996 PMC: 11430569. DOI: 10.3390/curroncol31090368.

Targeted Therapy in Mesotheliomas: Uphill All the Way.

Bertoli E, De Carlo E, Bortolot M, Stanzione B, Del Conte A, Spina M Cancers (Basel). 2024; 16(11).

PMID: 38893092 PMC: 11171080. DOI: 10.3390/cancers16111971.

Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse....

Garofalo M, Wieczorek M, Anders I, Staniszewska M, Lazniewski M, Prygiel M Front Oncol. 2023; 13:1259314.

PMID: 38053658 PMC: 10694471. DOI: 10.3389/fonc.2023.1259314.

References

Taioli E, Wolf A, Flores R . Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2014; 99(2):472-80. DOI: 10.1016/j.athoracsur.2014.09.056. View

Davis A, Kao S, Clarke S, Boyer M, Pavlakis N . Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opin Emerg Drugs. 2021; 26(2):179-192. DOI: 10.1080/14728214.2021.1924670. View

Calabro L, Morra A, Giannarelli D, Amato G, DIncecco A, Covre A . Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018; 6(6):451-460. DOI: 10.1016/S2213-2600(18)30151-6. View

Lim E, Darlison L, Edwards J, Elliott D, Fennell D, Popat S . Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020; 10(9):e038892. PMC: 7467531. DOI: 10.1136/bmjopen-2020-038892. View

Meyerhoff R, Yang C, Speicher P, Gulack B, Hartwig M, DAmico T . Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015; 196(1):23-32. PMC: 4430361. DOI: 10.1016/j.jss.2015.01.043. View

Gomez D, Hong D, Allen P, Welsh J, Mehran R, Tsao A . Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2012; 8(2):238-45. PMC: 5610569. DOI: 10.1097/JTO.0b013e31827740f0. View

van Gerwen M, Alpert N, Wolf A, Ohri N, Lewis E, Rosenzweig K . Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database. Carcinogenesis. 2019; 40(4):529-536. PMC: 6556702. DOI: 10.1093/carcin/bgz004. View

Cho B, Donahoe L, Bradbury P, Leighl N, Keshavjee S, Hope A . Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021; 22(2):190-197. DOI: 10.1016/S1470-2045(20)30606-9. View

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

10.

Busacca S, Sheaff M, Arthur K, Gray S, OByrne K, Richard D . BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol. 2011; 227(2):200-8. DOI: 10.1002/path.3979. View

11.

Stahel R, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A . Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015; 16(16):1651-8. DOI: 10.1016/S1470-2045(15)00208-9. View

12.

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D . Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026):1405-1414. DOI: 10.1016/S0140-6736(15)01238-6. View

13.

Nowak A, Lesterhuis W, Kok P, Brown C, Hughes B, Karikios D . Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020; 21(9):1213-1223. DOI: 10.1016/S1470-2045(20)30462-9. View

14.

Maio M, Scherpereel A, Calabro L, Aerts J, Perez S, Bearz A . Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017; 18(9):1261-1273. DOI: 10.1016/S1470-2045(17)30446-1. View

15.

Yap T, Aerts J, Popat S, Fennell D . Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017; 17(8):475-488. DOI: 10.1038/nrc.2017.42. View

16.

de Gooijer C, Borm F, Scherpereel A, Baas P . Immunotherapy in Malignant Pleural Mesothelioma. Front Oncol. 2020; 10:187. PMC: 7047444. DOI: 10.3389/fonc.2020.00187. View

17.

Migliore M, Ried M, Molins L, Lucchi M, Ambrogi M, Molnar T . Hyperthermic intrathoracic chemotherapy (HITHOC) should be included in the guidelines for malignant pleural mesothelioma. Ann Transl Med. 2021; 9(11):960. PMC: 8263862. DOI: 10.21037/atm-20-7247. View

18.

Alley E, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B . Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5):623-630. DOI: 10.1016/S1470-2045(17)30169-9. View

19.

Spirtas R, Heineman E, Bernstein L, BEEBE G, KEEHN R, Stark A . Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994; 51(12):804-11. PMC: 1128120. DOI: 10.1136/oem.51.12.804. View

20.

Alpert N, van Gerwen M, Taioli E . Epidemiology of mesothelioma in the 21 century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020; 9(Suppl 1):S28-S38. PMC: 7082259. DOI: 10.21037/tlcr.2019.11.11. View